Flash e-reader

 Go to e-reader chapter








PDF FormatRequires Adobe Acrobat Reader

Table 10.6h

Persistency of Discharge Regimen by Follow-up Period, 2004 to 2008

Recipients with Intestine Transplants

  Year of Transplant
2004 2005 2006 2007 2008
Discharge Regimen (w/ or w/o Steroid Use) Tac+Aza At Discharge (N) - - 1 3 -
At Discharge (%) - - 100.0% 100.0% -
6 Months PostTx (%) - - 100.0% 66.7% -
1 Year PostTx (%) - - 100.0% 66.7% -
2 Years PostTx (%) - - 100.0% 66.7% -
3 Years PostTx (%) - - 100.0% 66.7% -
Tac+MMF At Discharge (N) 11 19 26 33 39
At Discharge (%) 100.0% 100.0% 100.0% 100.0% 100.0%
6 Months PostTx (%) 80.0% 73.7% 42.3% 66.7% 97.4%
1 Year PostTx (%) 70.0% 52.6% 42.3% 47.1% 69.4%
2 Years PostTx (%) 70.0% 52.6% 37.6% 47.1% -
3 Years PostTx (%) 60.0% 47.4% 28.2% 18.9% -
Tac+Siro At Discharge (N) 14 18 14 13 16
At Discharge (%) 100.0% 100.0% 100.0% 100.0% 100.0%
6 Months PostTx (%) 71.4% 83.3% 78.6% 38.5% 62.5%
1 Year PostTx (%) 50.0% 50.0% 28.6% 23.1% 50.0%
2 Years PostTx (%) 50.0% 33.3% 28.6% 15.4% 50.0%
3 Years PostTx (%) 35.7% 27.8% 21.4% - -


Source: OPTN/SRTR Data as of October 1, 2010.

Regimen change is defined as being on different drug combination at follow-up comparing to discharge, or indication of conflicting regimen

(CyA vs. Tac; MMF/MPA vs. Aza; Siro vs. Evero) during follow-up period, or graft failure/death. Addition or deletion of steroids is not considered a regimen change.&

Rates are calculated for the most common discharge regimens.

CyA: Cyclosporine; Tac: Tacrolimus; MMF: Include MMF(Mycophenolate Mofetil) and MPA(Mycophenolate Sodium); Aza: Azathioprine; Siro: Sirolimus.

See Technical Notes for further details.